Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 (0) 1494 818026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
laura@zenopa.com
+44 (0) 1494 818026

Testimonials
I just wanted to express a massive Thank You to Zenopa for all the hard work you have done for me over the last 13 months.
Claire, 2012

GlaxoSmithKline reports positive phase III data for HIV drug

11 July 2012 11:26 in Pharmaceutical Company Product News


GlaxoSmithKline has unveiled encouraging clinical trial data for the once-daily HIV treatment dolutegravir via Shionogi-ViiV Healthcare.

The integrase inhibitor demonstrated superiority in a phase III study against the market-leading drug Atripla, which is manufactured by Gilead.

At 48 weeks, 88 percent of study participants taking dolutegravir were virologically suppressed, compared with 81 percent of patients using Atripla.

Shionogi-ViiV Healthcare is a joint venture between Japanese pharmaceutical firm Shionogi and ViiV, the company set up by GlaxoSmithKline and Pfizer in 2009 to focus on HIV treatments.

Dr John Pottage, chief medical officer at ViiV Healthcare, described the phase III data for dolutegravir as "an important milestone in the development of dolutegravir-based regimens, including a single-tablet regimen, and also for the Shionogi-ViiV Healthcare joint venture".

Full results of the study, which is the second of four phase III trials of the drug being completed this year, are due to be presented at forthcoming scientific meetings.ADNFCR-8000103-ID-801404909-ADNFCR

Other news stories from 11/07/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd